# **Stock Digest**

Wednesday, 23 Aug, 2023

# **Teo Seng Capital Bhd**

## Significantly above our earnings expectations

### **Summary**

- Significantly above our expectations. 2Q23 core net profit soared 565.9% YoY and 30.4% QoQ, respectively to RM25.4m, bringing the 6MFY23 earnings to RM44.8m. The results came in above expectations, amounting to 91.1% of our full year forecast at RM49.2m. Key deviations were mainly due to the higher-than-expected selling price of chicken eggs as well as softer-than-expected feed costs prices.
- **QoQ.** A drop in revenue by 3.1% was noticed, no thanks to marginally lower selling price of eggs. However, TEOSENG's core net profit increased 30.4% QoQ, amid lower feed costs prices coupled with egg subsidy received from the government's grant.
- YoY. Revenue rose 12.9%, while the core net profit soared 565.9% mainly due to higher average selling price of eggs and sales volume.
- **YTD**. Similarly, 6MFY23's results were growing on the back of higher average selling price of eggs and sales quantity, coupled with normalised feed costs prices.
- **Outlook.** We expect TEOSENG's performance to remain steady on an upward trend at least for the near term, with the stabilized maize and soybean meal prices. Meanwhile, the reopening of business activities locally since last year and the China reopening of borders since January 2023 will be able to help the overall demand and expect the chicken egg prices to continue its upward tone. Should the price control ceiling being removed there will be upside earnings potential for TEOSENG. We believe the effort of reducing the electricity costs with the commissioning of the PV system as well as the proactive measures to expand its customer base through e-commerce will be earnings accretive.

Quarterly performance								
FYE Dec (RM m)	2QFY22	1QFY23	2QFY23	QoQ (%)	YoY (%)	6MFY22	6MFY23	YoY (%)
Revenue	157.4	183.4	177.7	(3.1)	12.9	304.7	361.1	18.5
EBITDA	10.3	33.2	31.6	(4.8)	207.5	22.0	64.8	194.9
РВТ	2.5	24.4	22.6	(7.3)	819.4	6.2	47.0	659.1
Core PATMI	3.8	19.5	25.4	30.4	565.9	7.9	44.8	468.7
Reported PATMI	3.9	19.7	25.4	29.0	546.0	8.1	45.1	457.1
Core EPS (sen)	1.3	6.6	8.6	30.4	565.9	2.7	15.3	468.7
EBITDA margin (%)	6.5	18.1	17.8			7.2	17.9	
PBT margin (%)	1.6	13.3	12.7			2.0	13.0	
Core PATMI margin (%)	2.4	10.6	14.3			2.6	12.4	

## Valuation & Recommendation

 Although TEOSENG's outlook has turned brighter amid the improved outlook on chicken eggs prices, we are ceasing coverage on TEOSENG due to reallocation of internal resources. Our last recommendation on TEOSENG was **BUY** with a fair value of RM1.34, derived by ascribing PER of 8.0x to its FY23f EPS of 16.8 sen.

Malacca Securities Sdn Bhd mplusonline.com/research-reports

#### Ceasing Coverage Note - 2QFY23

Loui Low Ley Yee louilow@msec.com.my (603) 2201 2100

### BUY

Share price	RM0.88
Target price	
Previous TP	RM1.34
Capital upside	-
Dividend return	-
Total return	-

#### **Company profile**

Layer farming, manufacturing and marketing of animal feeds and paper egg trays, along with the distribution of animal health products.

Stock information	
Bursa Code	7252
Bloomberg ticker	TSCB MK
Listing market	Main
Share issued (m)	293.9
Market Cap (m)	317.0
52W High/Low	1.10/0.69
Est. Free float	31.3%
Beta (x)	0.4
3-mth avg vol ('000)	453.6
Shariah compliant	No

Major shareholders	%
Emerging Glory Sdn Bhd	54.6
SEB AB for Elvi E	4.4
Leong Hup Sdn Bhd	2.4

Share price v	s. KLCI	(%)	
Hist. return	1M	3M	12M
Absolute	6.0	14.3	9.3
Relative	7.4	19.7	19.1
Earnings sum	nmary		
FYE (Dec)	FY22	FY23f	FY24f
PATMI (m)	21.2	49.2	57.7
EPS (sen)	7.2	16.8	19.6


12.2

5.3

4.5

#### Relative performance chart

P/E(x)



Aug-22 Nov-22 Jan-23 Mar-23 May-23 Aug-23

# **Stock Digest**

Wednesday, 23 Aug, 2023

# line Malacca Securities Sdn Bhd mplusonline.com/research-reports

# **Financial Highlights**

#### All items in (RM m) unless otherwise stated

Income Statement						Balance Sheet					
FYE Dec (RM m)	FY20	FY21	FY22	FY23f	FY24f	FYE Dec (RM m)	FY20	FY21	FY22	FY23f	FY24f
Revenue	478.3	530.1	652.0	698.7	744.4	Cash	44.9	49.0	41.1	84.3	117.1
EBITDA	39.5	30.1	61.0	99.8	112.6	Receivables	53.4	67.0	67.0	71.8	76.5
EBIT	16.3	5.9	35.2	72.8	84.3	Inventories	48.2	58.6	71.0	64.9	63.9
Net finance income/ (cost)	(6.2)	(6.0)	(6.3)	(5.8)	(5.7)	PPE	373.6	373.4	375.2	378.6	380.7
Associates & JV	-	-	-	-	-	Others	70.8	74.3	65.9	70.1	74.5
Profit before tax	10.0	(0.2)	28.9	67.1	78.6	Assets	591.0	622.4	620.2	669.7	712.7
Tax	(6.6)	(1.8)	(7.7)	(17.8)	(20.9)						
Netprofit	3.4	(2.0)	21.2	49.2	57.7	Debts	174.2	205.0	171.3	171.6	169.0
Minority interest	-	-	-	-	-	Payables	54.6	62.9	72.1	81.0	79.7
Coreearnings	3.4	(2.0)	21.2	49.2	57.7	Others	54.2	43.0	42.1	43.2	43.8
Exceptional items	(0.8)	(5.0)	(0.5)	-	-	Liabilities	282.9	310.9	285.6	295.7	292.6
Reported earnings	4.2	3.0	21.6	49.2	57.7						
						Shareholder's equity	308.0	311.5	334.6	374.0	420.2
						Minority interest	-	-	-	-	-
Cash Flow Statement						Equity	308.0	311.5	334.6	374.0	420.2

FYE Dec (RM m)	FY20	FY21	FY22	FY23f	FY24f
Profit before taxation	10.0	(0.2)	28.9	67.1	78.6
Depreciation & amortisation	23.2	24.3	25.7	26.9	28.3
Changes in working capital	3.7	(15.6)	(3.2)	10.1	(4.9)
Share of JV profits	-	-	-	-	-
Taxation	(6.6)	(1.8)	(7.7)	(17.8)	(20.9)
Others	1.7	2.8	11.7	(3.2)	(3.7)
Operating cash flow	32.1	9.5	55.4	83.1	77.4
Net capex	(47.5)	(23.8)	(24.9)	(30.4)	(30.4)
Others	2.7	3.9	7.1	-	-
Investing cash flow	(44.8)	(20.0)	(17.8)	(30.4)	(30.4)
Changes in borrowings	34.6	30.8	(33.7)	0.3	(2.6)
Issuance of shares	0.0	-	-	-	-
Dividends paid	-	-	-	(9.8)	(11.5)
Others	(19.8)	(14.5)	(11.9)	-	-
Financing cash flow	14.7	16.3	(45.6)	(9.5)	(14.1)
Net cash flow	2.0	5.8	(8.0)	43.2	32.9
Forex	(0.0)	0.1	0.0	-	-
Others	1.8	(1.8)	0.0	-	-
Beginning cash	41.1	44.9	49.0	41.1	84.3
Ending cash	44.9	49.0	41.1	84.3	117.1

Minority interest					
Equity	308.0	311.5	334.6	374.0	420.2
Valuation & Ratios					
FYE Dec (RM m)	FY20	FY21	FY22	FY23f	FY24
Core EPS (sen)	1.2	(0.7)	7.2	16.8	19.6
P/E (x)	75.2	NM	12.2	5.3	4.5
DPS (sen)	-	-	-	3.4	3.9
Dividend yield	0.0%	0.0%	0.0%	3.8%	4.5
BVPS (RM)	1.05	1.06	1.14	1.27	1.43
P/B (x)	0.8	0.8	0.8	0.7	0.6
EBITDA margin	8.3%	5.7%	9.3%	14.3%	15.1
EBIT margin	3.4%	1.1%	5.4%	10.4%	11.3
PBT margin	2.1%	0.0%	4.4%	9.6%	10.6
PAT margin	0.9%	0.6%	3.3%	7.0%	7.8
Core PA⊤ margin	0.7%	-0.4%	3.2%	7.0%	7.8
ROE	1.1%	-0.6%	6.6%	13.9%	14.5
ROA	0.6%	-0.3%	3.4%	7.6%	8.4
Net gearing	42.0%	50.1%	38.9%	23.4%	12.4

2

#### Disclaimer

Research analyst(s) of MSSB whom produced this report hereby certifies that the views expressed in this report accurately reflect his/her personal opinions about all of the subject corporation(s) and securities in this report. He/She does not carry out, whether for himself/herself or on behalf of MSSB or any other persons did not receive and will not receive any compensation that is directly or indirectly related or linked to the recommendations or views expressed in this report or to any sales, trading, dealing or corporate finance advisory services or transaction in respect of the securities in this report. As of the report date, the analyst whom prepared this report does not have any interest in the following securities covered in this report, unless otherwise stated.

As of Wednesday, 23 Aug, 2023, the analyst(s), Loui Low Ley Yee, whose name(s) appears on the front page, who prepared this report, has interest in the following securities covered in this report:

(a) nil.

Stock recommend	dation guide
BUY	The share price is expected to appreciate more than 10% over the next 12 months
HOLD	The stock price is expected to range between -10% and +10% over the next 12 months
SELL	The share price is expected to fall more than 10% over the next 12 months
TRADING BUY	The share price is projected to rise more than 10% over the next three (3) months due to an ongoing or impending corporate development. The stock price is also expected to be volatile over the next three months
TRADING SELL	The stock price is expected to fall more than 10% over the next three months due to an ongoing or impending corporate developments. The stock price is also expected to be volatile over the next three months
NOT RATED	No recommendation is assigned